These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27176505)

  • 1. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
    Nathwani SM; Greene LM; Butini S; Campiani G; Williams DC; Samali A; Szegezdi E; Zisterer DM
    Int J Oncol; 2016 Jul; 49(1):74-88. PubMed ID: 27176505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.
    Maginn EN; Browne PV; Hayden P; Vandenberghe E; MacDonagh B; Evans P; Goodyer M; Tewari P; Campiani G; Butini S; Williams DC; Zisterer DM; Lawler MP; McElligott AM
    Br J Cancer; 2011 Jan; 104(2):281-9. PubMed ID: 21179037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
    Kinsella P; Greene LM; Bright SA; Pollock JK; Butini S; Campiani G; Bauer S; Williams DC; Zisterer DM
    Invest New Drugs; 2016 Apr; 34(2):159-67. PubMed ID: 26885657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells.
    Greene LM; Nolan DP; Regan-Komito D; Campiani G; Williams DC; Zisterer DM
    Int J Oncol; 2013 Sep; 43(3):927-35. PubMed ID: 23799546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells.
    Lennon JC; Bright SA; Carroll E; Butini S; Campiani G; O'Meara A; Williams DC; Zisterer DM
    Biochem Pharmacol; 2014 Feb; 87(4):611-24. PubMed ID: 24406249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
    Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
    Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
    Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
    Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnolol Enhances the Therapeutic Effects of TRAIL through DR5 Upregulation and Downregulation of c-FLIP and Mcl-1 Proteins in Cancer Cells.
    Woo SM; Min KJ; Kwon TK
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
    Shlyakhtina Y; Pavet V; Gronemeyer H
    Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
    Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
    Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
    Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4973-80. PubMed ID: 17510428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
    Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
    J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells.
    Dida F; Li Y; Iwao A; Deguchi T; Azuma E; Komada Y
    Exp Hematol; 2008 Oct; 36(10):1343-53. PubMed ID: 18599181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.